Sun Pharma Advanced Research Company Ltd Stock Analysis

BSE: 532872 | NSE: SPARC | Miscellaneous | Mid Cap

BSE Share Price 02-Dec-2022 18:01
253.90 -2.10 (-0.82%)

DeciZen - Make an Informed Decision on Sun Pharma Adv. Res

Overall Rating

1. Quality

2. Valuation

Fair

3. Price Trend

Sun Pharma Adv. Res Price Chart

P/E Ratio (SA) :
0.00
Market Cap :
6,990.6 Cr.
52-wk low :
172.5
52-wk high :
348.8
Bole Toh?

1. Is Sun Pharma Advanced Research Company Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company.

2. Is Sun Pharma Advanced Research Company Ltd undervalued or overvalued?

The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Sun Pharma Advanced Research Company Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Sun Pharma Adv. Res:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sun Pharma Advanced Research Company Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % -21.1%18%-31.8%-71.3%-95.7%-134.4%-59.5%-180.1%-264%-233.7%-
Value Creation Index -2.50.3-3.3-6.3-8.1-11.0-5.3NANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 87.316715616118178.318376.8253137147
YoY Gr. Rt. %-91.4%-6.8%3.6%12.2%-56.8%133.7%-58%229.3%-45.7%-
Adj EPS -11.1-1.7-3-4.9-9.3-5.5-12-5.9-7.6-8.6
YoY Gr. Rt. %-NA-252.3%NANANANANANANA-
BVPS (₹) 4.55.84.21.26.43.711.3-0.7-6.4-7.5-12.8
Adj Net Profit -2326.1-39.6-69.8-120-234-144-314-153-206-238
Cash Flow from Ops. -95.336.9-41.2-44.2-128-183-172-211-152-208-
Debt/CF from Ops. -0.90.1-0.1-1.3-0-0-0-0.3-1.5-0.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.2%-5.4%-9.1%-45.7%
Adj EPS NANANANA
BVPS -205.7-203.1-187.10
Share Price 7.7% -10.4% 17.6% -0.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -109.821-33.2-106.1-126.7-136.6-60-226164.230185
Op. Profit Mgn % -1920.1-22.5-39-67.7-310-79.1-397.7-53.4-135.5-148.3
Net Profit Mgn % -26.315.6-25.4-43.3-66.5-299.2-78.9-408.3-60.7-150.3-161.2
Debt to Equity 0.8001.9000-3.6-1.4-0.4-
Working Cap Days 110161200163210641254554177355209
Cash Conv. Cycle -27-63-80-130-170-113-272-254-119-600

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 85.00%

Sales growth is good in last 4 quarters at 54.38%

Sales growth has been subdued in last 3 years 0.00%

Latest Financials - Sun Pharma Advanced Research Company Ltd.

Standalone Consolidated
TTM EPS (₹) -8.6 -
TTM Sales (₹ Cr.) 147 -
BVPS (₹.) -12.8 -
Reserves (₹ Cr.) -381 -
P/BV -19.78 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 172.45 / 348.75
All Time Low / High (₹) 38.44 / 593.93
Market Cap (₹ Cr.) 6,991
Equity (₹ Cr.) 27.5
Face Value (₹) 1
Industry PE 26.1

Management X-Ray of Sun Pharma Adv. Res :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *1.901.900.752.292.292.292.292.182.181.65
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sun Pharma Adv. Res

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Sun Pharma Advanced Research Company Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sun Pharma Adv. Res on 02-Dec-2022 18:01 is : 253.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Sun Pharma Adv. Res stood at ₹ 6,990.6.
The latest PE ratio of Sun Pharma Adv. Res as of 02-Dec-2022 18:01 is 0.00.
The latest PB ratio of Sun Pharma Adv. Res as of 02-Dec-2022 18:01 is -19.78
The 52-week high of Sun Pharma Adv. Res is ₹ 348.8 and the 52-week low is ₹ 172.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Sun Pharma Adv. Res is ₹ 147.4 ( Cr.) .

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

  • Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
  • Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
  • Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

  • 2006: SPARC is founded in Vadodara, India
  • 2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
  • 2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
  • 2012: 1st NDA filed with USFDA for Elepsia XR
  • 2012: Raised Rs. 200 crore through Rights Issue
  • 2013: Filed NDA for Xelpros with USFDA
  • 2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
  • 2015: Entered into research collaboration in the field of Oncology with US University
  • 2015: Launched Bevetex (PICS) in India
  • 2016: Raised Rs. 250 crore through Rights Issue
  • 2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
  • 2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
  • 2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
  • 2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
  • 2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
  • 2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
  • 2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
  • 2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
  • 2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
  • 2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now